KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31
Karyopharm Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.35−0.04 (-11.30%)
Close on Oct 19, 2026
- Market cap
- $10.01K
- P/E (TTM)
- –
- Dividend yield
- –
Karyopharm Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $30.78M | $29.16M | $32.09M | $32.03M | $29.68M | $21.05M | $29.25M | $29.52M | $28.03M | $26.01M | $25.06M | $30.21M | 92.1% | +3.7% |
| License and Other [Member] | $2.66M | $5.90M | $1.99M | $12.01M | $8.25M | $8.96M | $1.29M | $9.27M | $14.75M | $7.12M | $8.69M | $5.80M | 7.9% | -67.8% |
By region
From the segment and revenue-disaggregation notes of Karyopharm Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.